PMID- 28061827
OWN - NLM
STAT- MEDLINE
DCOM- 20170714
LR  - 20231213
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Jan 7
TI  - Systematic review and network meta-analysis of tedizolid for the treatment of 
      acute bacterial skin and skin structure infections caused by MRSA.
PG  - 39
LID - 10.1186/s12879-016-2100-3 [doi]
LID - 39
AB  - BACKGROUND: Tedizolid, the active moiety of tedizolid phosphate, is approved in 
      the United States, the European Union, Canada and a number of other countries for 
      the treatment of acute bacterial skin and skin structure infections (ABSSSI) 
      caused by certain susceptible bacteria, including methicillin-resistant 
      Staphylococcus aureus (MRSA). This network meta-analysis (NMA) evaluates the 
      comparative effectiveness of tedizolid and other antibacterials indicated for the 
      treatment of ABSSSI caused by MRSA. METHODS: Systematic review of 10 databases 
      was undertaken to inform an NMA to estimate the relative effectiveness of 
      tedizolid and established monotherapy comparators (ceftaroline, daptomycin, 
      linezolid, teicoplanin, tigecycline, vancomycin) for treating MRSA-associated 
      ABSSSI. Randomized controlled trials enrolling adults with ABSSSI or complicated 
      skin and skin structure infections caused by suspected/documented MRSA were 
      eligible for inclusion. Networks were developed based on similarity of study 
      design, patient characteristics, outcome measures and available data. Outcomes of 
      interest included clinical response at end of therapy (EOT), post-therapy 
      evaluation (PTE) or test-of-cure assessment and treatment discontinuations 
      resulting from adverse events (AEs). Bayesian NMA was conducted for each outcome 
      using fixed-effects and random effects models. RESULTS: Literature searches 
      identified 3,618 records; 15 trials met the inclusion criteria and were 
      considered suitable for NMA comparison. In fixed-effects models, tedizolid had 
      higher odds of clinical response at EOT (odds ratio [OR], 1.7; credible interval, 
      1.0, 3.0) and PTE than vancomycin (OR, 1.6; credible interval, 1.1, 2.5). No 
      differences in odds of clinical response at EOT or PTE were observed between 
      tedizolid and other comparators. There was no evidence of a difference among 
      treatments for discontinuation due to AEs. Results from random effects and 
      fixed-effects models were generally consistent. CONCLUSIONS: Tedizolid was 
      superior to vancomycin for clinical response at EOT and PTE. There was no 
      evidence of a difference between tedizolid and other comparators and no evidence 
      of a difference between tedizolid and all comparators when evaluating 
      discontinuation due to AEs. These findings suggest that tedizolid provides an 
      alternative option for the management of serious skin infections caused by 
      suspected or documented MRSA. This study is subject to the limitations inherent 
      in all NMAs, and the results should be interpreted accordingly.
FAU - McCool, Rachael
AU  - McCool R
AD  - York Health Economics Consortium, Enterprise House, Innovation Way, University of 
      York, Heslington, York, YO10 5NQ, UK. Rachael.mccool@york.ac.uk.
FAU - Gould, Ian M
AU  - Gould IM
AD  - Aberdeen Royal Infirmary, Foresterhill Road, Aberdeen, AB25 2ZN, UK.
FAU - Eales, Jacqui
AU  - Eales J
AD  - York Health Economics Consortium, Enterprise House, Innovation Way, University of 
      York, Heslington, York, YO10 5NQ, UK.
FAU - Barata, Teresa
AU  - Barata T
AD  - Quantics, 28 Drumsheugh Gardens, Edinburgh, EH3 7RN, UK.
FAU - Arber, Mick
AU  - Arber M
AD  - York Health Economics Consortium, Enterprise House, Innovation Way, University of 
      York, Heslington, York, YO10 5NQ, UK.
FAU - Fleetwood, Kelly
AU  - Fleetwood K
AD  - Quantics, 28 Drumsheugh Gardens, Edinburgh, EH3 7RN, UK.
FAU - Glanville, Julie
AU  - Glanville J
AD  - York Health Economics Consortium, Enterprise House, Innovation Way, University of 
      York, Heslington, York, YO10 5NQ, UK.
FAU - Kauf, Teresa L
AU  - Kauf TL
AD  - Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20170107
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Cephalosporins)
RN  - 0 (Organophosphates)
RN  - 0 (Oxazoles)
RN  - 0 (Oxazolidinones)
RN  - 0 (Tetrazoles)
RN  - 6Q205EH1VU (Vancomycin)
RN  - 97HLQ82NGL (tedizolid)
RN  - ISQ9I6J12J (Linezolid)
RN  - NWQ5N31VKK (Daptomycin)
RN  - O7DRJ6R4DW (tedizolid phosphate)
SB  - IM
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Bayes Theorem
MH  - Cephalosporins/therapeutic use
MH  - Daptomycin/therapeutic use
MH  - Humans
MH  - Linezolid/therapeutic use
MH  - Methicillin-Resistant Staphylococcus aureus/*pathogenicity
MH  - Organophosphates/therapeutic use
MH  - Oxazoles/therapeutic use
MH  - Oxazolidinones/*therapeutic use
MH  - Skin Diseases, Bacterial/*drug therapy
MH  - Staphylococcal Infections/*drug therapy
MH  - Tetrazoles/*therapeutic use
MH  - Vancomycin/therapeutic use
MH  - Ceftaroline
PMC - PMC5219662
OTO - NOTNLM
OT  - Acute bacterial skin and skin structure infections
OT  - Antibacterial
OT  - Complicated skin and skin structure infections
OT  - Methicillin-resistant Staphylococcus aureus
OT  - Network meta-analysis
OT  - Systematic review
EDAT- 2017/01/08 06:00
MHDA- 2017/07/15 06:00
PMCR- 2017/01/07
CRDT- 2017/01/08 06:00
PHST- 2016/04/28 00:00 [received]
PHST- 2016/12/07 00:00 [accepted]
PHST- 2017/01/08 06:00 [entrez]
PHST- 2017/01/08 06:00 [pubmed]
PHST- 2017/07/15 06:00 [medline]
PHST- 2017/01/07 00:00 [pmc-release]
AID - 10.1186/s12879-016-2100-3 [pii]
AID - 2100 [pii]
AID - 10.1186/s12879-016-2100-3 [doi]
PST - epublish
SO  - BMC Infect Dis. 2017 Jan 7;17(1):39. doi: 10.1186/s12879-016-2100-3.